Organizing Committee of the Lugano Classification Workshop
Organizing Committee of the Lugano Classification Workshop
In the decade since publication of the Lugano Classification (Cheson et al, J Clin Oncol 2014,32:3059-3068; Barrington et al, J Clin Oncol 2014, 32:3048-3058), major advances in lymphoma therapy and assessment, including metabolic tumor vol...
18th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 17 - 21 June, 2025 [0.03%]
第二十八届国际恶性淋巴瘤大会将在瑞士卢加诺的Palazzo dei Congressi会议中心举行，时间是2025年6月17-21日
A Sureda Balari,M Hertzberg,J Radford et al.
A Sureda Balari et al.
Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Update on Biology and Treatment [0.03%]
淋巴细胞为主型霍奇金淋巴瘤的病理和治疗进展
Peter Borchmann,Dennis A Eichenauer,Gerard Frigola et al.
Peter Borchmann et al.
Nodular lymphocyte-predominant B-cell/Hodgkin lymphoma (NLPB/HL) accounts for roughly 5% of all Hodgkin lymphoma (HL) cases. In contrast to classic HL (cHL), the malignant cells in NLPB/HL lack CD30 expression but maintain a complete phenot...
Marginal Zone Lymphoma: Treatment Update With a Focus on Systemic Approaches [0.03%]
边缘区淋巴瘤治疗进展：系统性治疗方案聚焦
Sonali M Smith
Sonali M Smith
Marginal zone lymphoma (MZL) is the second most common indolent B-cell lymphoma and comprised of three clinical subtypes based on site of involvement: extranodal marginal zone lymphoma (usually of mucosa-associated lymphoid tissue), nodal m...
First Line Therapy in Mantle Cell Lymphoma-The Role of BTKi in the Initial Treatment of Transplant-Eligible and -Ineligible Patients [0.03%]
套细胞淋巴瘤一线治疗：BTK抑制剂在适合和不适合移植患者初始治疗中的作用
E Silkenstedt,M Dreyling
E Silkenstedt
The development and implementation of new targeted and immunotherapeutic approaches in the treatment landscape of mantle cell lymphoma have already improved therapeutic options especially for refractory or relapsed disease. Regarding first-...
Steven P Treon,Shayna Sarosiek,Jorge J Castillo
Steven P Treon
Waldenström macroglobulinemia (WM) is an IgM secreting lymphoplasmacytic lymphoma. Mutations in MYD88 (95%-97%) and CXCR4 (30%-40%) are common in patients with WM. TP53 is also altered in up to 30% of WM patients, particularly those previo...
Diagnosis and Management of Large Granular Lymphocytic Leukaemia and Its Differentiation From T Cell Clones of Uncertain Significance [0.03%]
大颗粒淋巴细胞白血病的诊断和治疗及其与意义不明T细胞克隆的区别
Dima El-Sharkawi,Claire Dearden
Dima El-Sharkawi
Large granular lymphocytic leukemia (LGLL) is a chronic clonal T- or NK-cell disorder that can cause significant cytopenias. Different phenotypes and genotypes have been associated with different clinical courses. LGLL can be associated wit...
Advancing Mantle Cell Lymphoma Risk Assessment: Navigating a Moving Target [0.03%]
推进套细胞淋巴瘤风险评估：应对变化的目标
Simone Ferrero,Simone Ragaini
Simone Ferrero
Mantle cell lymphoma (MCL) is a B-cell malignancy characterized by t(11;14)(q13;q32) translocation and heterogeneous clinical behavior. Advances in risk stratification enabled the distinction of conventional MCL (cMCL) from non-nodal MCL (n...